Anthem Biosciences Share Price Today

Anthem Biosciences settles ₹1,276.83 million upside sharing arrangement

Anthem Biosciences settled an upside sharing arrangement of ₹1,276.83 million. Payment made to principal shareholders Ajay Bhardwaj, Ganesh Sambasivam, and K. Ravindra Chandrappa. Settlement follows AGM approval on July 22, 2026, regarding Viridity Tone LLP divestment. Transaction executed per Waiver-cum-Amendment Agreement dated December 30, 2024.

Anthem Biosciences sees Q1 revenue dip but maintains FY27 growth outlook

Anthem Biosciences delivered Q1FY27 results showing a 22.6% revenue drop to ₹4,182 Mn, driven by deferred customer deliveries in the CRDMO segment. Despite lower sales, PAT declined only 11.7% to ₹1,199 Mn, supported by improved EBITDA margins of 39.6%. The company maintains a strong balance sheet with ₹17,197 Mn in net cash and has secured 60% of its annual order book, reinforcing confidence in achieving historical growth rates for FY27 amidst ongoing Unit 4 expansion.

Anthem Biosciences passes all eight AGM resolutions with high voter turnout

Anthem Biosciences concluded its 20th AGM with approval of all resolutions, including FY26 financials, dividend, auditor appointment, and strategic partnerships. High voter turnout reflected strong engagement, though institutional dissent emerged on governance and related-party matters.

Anthem Biosciences Expresses Confidence in Regaining Mid-Teens Growth Rate

Anthem Biosciences has expressed confidence in regaining its mid-teens growth rate, reflecting a positive stance on its business outlook. The company's statement highlights its belief in returning to stronger growth levels. No specific financial metrics or timelines were detailed in the available source data.

Anthem Biosciences confirms no encumbrance on promoter shares in FY26

Anthem Biosciences confirmed via a regulatory filing that its promoter group, led by Ishaan Bhardwaj, did not encumber any shares during FY26. The disclosure, submitted to BSE and NSE under SEBI takeover regulations, listed eight promoter group members, including foreign nationals, and confirmed compliance with required transparency norms.

Anthem Biosciences sets AGM for July 22 to approve ₹2 dividend

Anthem Biosciences Limited has announced its 20th Annual General Meeting for July 22, 2026, to be held virtually. The primary agenda includes the approval of a final dividend of ₹2 per equity share for the financial year ended March 31, 2026. Shareholders of record as of June 26, 2026, will be eligible for the dividend, which is to be paid by August 21, 2026. The meeting will also address the appointment of statutory auditors, remuneration for independent directors and related parties, and an upside sharing arrangement with Viridity Tone LLP.